ElectroCore, Inc. announced positive data from a study presented at the 2025 International Brain Injury Association World Congress, showing the effectiveness of their non-invasive vagus nerve stimulation (nVNS) device, gammaCore, in treating concussive symptoms linked to mild traumatic brain injury (mTBI). The study, involving 102 patients, demonstrated significant improvement in 22 out of 27 measured symptoms, including post-traumatic headache, nausea, dizziness, and depression, regardless of the time elapsed since the injury. This research was presented by Dr. Michael Ament of Cherry Creek Neurology.
This positive data is a crucial advancement for the mTBI treatment landscape, where effective, non-pharmaceutical options are critically needed. Current treatments for mTBI often fall short in addressing the diverse and persistent symptoms that significantly impact patients’ quality of life. The study’s findings suggest that gammaCore could fill this unmet need, offering a potential new avenue for managing these debilitating symptoms and potentially accelerating recovery.
The study involved 102 patients with mTBI, and gammaCore was used as an adjunctive treatment. Notably, the improvement was observed across a range of symptoms, with the most significant improvements seen in headache, nausea, dizziness, and depression. Furthermore, the benefit was observed in both recent and older injuries, expanding the potential patient population for this therapy.
This data reinforces the potential of nVNS as a viable treatment option for mTBI, potentially transforming how concussive symptoms are managed. It opens the door for further research and development in nVNS therapies, offering hope for improved patient outcomes and a better quality of life for individuals suffering from the lingering effects of mTBI. This could lead to wider adoption of nVNS technology and establish gammaCore as a standard treatment option in mTBI care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
